Clinical trial
Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)
NCT02229149 is registered in ClinicalTrials.gov with US Oncology Research as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)
- Lead sponsor
- US Oncology Research
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2014
- Completion date
- January 31, 2022
- Enrollment
- 33 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast neoplasms, malignant tumor of the breast